Business & Finance
Theradiag generates revenues of EUR5.0m for H1 2019
25 September 2019 -

In vitro diagnostics company Theradiag (Paris:ALTER) (ISIN:FR0004197747) said on Tuesday that its board of directors announced revenues of EUR5.0m for the six months ended 30 June 2019.

This marks a growth of 9% when compared with revenues of EUR4.6m in H1 2018.

Net income including non-recurring items of EUR640000 were reported for the six months ended 30 June 2019, a growth versus net loss of EUR89,000 in H1 2018.

Through the distribution channels, the company's sales were up 27% over the same period last year, in line with the recently implemented distribution strategy and partnerships.

At 30 June 2019, the company recorded net cash of EUR3.2m, a dip over EUR3.4m at 31 December 2018 and EUR3.7m at 30 June 2018, but sufficient for upcoming investments in R&D in key international markets, in particular the US.